Apellis Pharmaceuticals, Inc.APLSNASDAQ
Loading
Year-over-year total asset growth rate
5Y CAGR
-42.6%/yr
Long-term compound
Percentile
P64
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 1.56% |
| Q3 2025 | 28.89% |
| Q2 2025 | 1.75% |
| Q1 2025 | -8.79% |
| Q4 2024 | -1.86% |
| Q3 2024 | -0.29% |
| Q2 2024 | 8.72% |
| Q1 2024 | 5.48% |
| Q4 2023 | -3.60% |
| Q3 2023 | -10.63% |
| Q2 2023 | -6.47% |
| Q1 2023 | 28.76% |
| Q4 2022 | -12.91% |
| Q3 2022 | -12.93% |
| Q2 2022 | -12.51% |
| Q1 2022 | 29.95% |
| Q4 2021 | 67.74% |
| Q3 2021 | -24.89% |
| Q2 2021 | -13.60% |
| Q1 2021 | -15.66% |
| Q4 2020 | 25.02% |
| Q3 2020 | -11.70% |
| Q2 2020 | 26.30% |
| Q1 2020 | 76.99% |
| Q4 2019 | -16.53% |
| Q3 2019 | 47.25% |
| Q2 2019 | -0.52% |
| Q1 2019 | 56.41% |
| Q4 2018 | -14.89% |
| Q3 2018 | -10.37% |
| Q2 2018 | 63.49% |
| Q1 2018 | -10.39% |
| Q4 2017 | 851.51% |
| Q3 2017 | -66.24% |
| Q2 2017 | 0.00% |
| Q1 2017 | -100.00% |
| Q4 2016 | 0.00% |
| Q3 2016 | 0.00% |
| Q2 2016 | 0.00% |
| Q1 2016 | -100.00% |